|Bid||1.45 x 1200|
|Ask||1.48 x 800|
|Day's Range||1.4300 - 1.4800|
|52 Week Range||0.7600 - 2.9000|
|Beta (3Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 13, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.60|
OpGen, Inc. (OPGN) announced today that it has completed the clinical trials needed to support its 510(k) submission for the detection of antimicrobial resistance genes in bacterial isolates to the U.S. Food & Drug Administration (“FDA”) for clearance of its Acuitas® AMR Gene Panel u5.47 product.
OpGen, Inc. (OPGN) today announced that it has provided the final report for completion of the contract from the Centers for Disease Control and Prevention (CDC) to develop smartphone-based clinical decision support solutions for antimicrobial stewardship (AMS) and infection control in low- and middle-income countries. OpGen worked with partners ILÚM Health Solutions, LLC (“ILÚM”), a wholly owned subsidiary of Merck’s Healthcare Services and Solutions, and Universidad El Bosque (UEB) of Bogota, Colombia led by Maria Virginia Villegas, M.D., M.Sc.
OpGen, Inc. (OPGN) announced today it has received approval from the Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia’s regulatory authority for food, drugs, and medical devices, to market its rapid pathogen identification products in the country. Earlier this year OpGen established a subsidiary, OpGen Colombia, SAS, to commercialize the Company’s precision medicine products in Colombia and more broadly through South America.
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of 3.64% and -1.43%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / OpGen, Inc. (NASDAQ: OPGN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern Time. To listen ...
Zacks.com featured highlights include: Hilton Grand, Fastenal, Catalyst Biosciences, OpGen and ConforMIS